Eosinophils drive Eosinophilic Esophagitis pathogenesis via type 2 cytokines, offering new therapeutic targets
Background
Eosinophilic esophagitis (EoE) is a chronic immune-mediated esophageal disease characterized by eosinophilic infiltration, epithelial barrier dysfunction, and progressive tissue remodeling. It is a leading cause of esophageal dysfunction worldwide. Current standard-of-care often involves dietary elimination or corticosteroids, but these do not always address the underlying immune dysregulation. Increasing evidence identifies eosinophils as central drivers of inflammation and fibrosis, linking EoE to type 2 immune responses and allergic disorders. However, the precise molecular mechanisms underlying eosinophil-mediated esophageal damage and their interaction with gastroesophageal reflux disease (GERD) remain incompletely understood.
Study Design
This comprehensive narrative review synthesized current literature on Eosinophilic Esophagitis (EoE), focusing on eosinophil biology, inflammatory signaling pathways, epithelial remodeling, fibrosis, and therapeutic targets. Researchers conducted a literature search using the MEDLINE (PubMed) database, critically analyzing clinical, translational, and experimental studies. The review evaluated the association between EoE, GERD, and allergic comorbidities, aiming to provide an updated perspective on the evolving role of eosinophils in EoE pathobiology and treatment approaches.
Results
Available evidence demonstrates that eosinophils actively contribute to EoE pathogenesis through the release of cytotoxic granule proteins, cytokines, chemokines, and lipid mediators, leading to chronic inflammation and fibrostenotic remodeling. Dysregulation of type 2 cytokines, particularly IL-4, IL-5, and IL-13, plays a pivotal role in disease progression and immune cell recruitment. Significant overlap between EoE and GERD suggests shared inflammatory mechanisms and diagnostic challenges, complicating patient management. Furthermore, EoE frequently coexists with systemic allergic diseases, supporting the concept of a broader atopic inflammatory phenotype. Emerging biologic therapies targeting eosinophilic and type 2 inflammatory pathways have shown promising efficacy in reducing symptoms and histologic activity. > Eosinophils represent key regulators of EoE pathobiology and constitute promising biomarkers and therapeutic targets, with a deeper understanding of eosinophil-driven inflammatory networks improving diagnostic accuracy and patient stratification.
Key Findings
- Eosinophils are central drivers of Eosinophilic Esophagitis (EoE) inflammation and fibrosis.
- Dysregulation of type 2 cytokines (
IL-4,IL-5,IL-13) is pivotal in EoE disease progression. - Significant overlap exists between EoE and GERD, suggesting shared inflammatory mechanisms.
- EoE frequently coexists with systemic allergic diseases, indicating a broader atopic phenotype.
- Emerging biologic therapies targeting eosinophilic and type 2 inflammatory pathways show promising efficacy.
Why It Matters
This review consolidates the understanding that eosinophils are not merely bystanders but active drivers of EoE pathology, shifting the focus from symptomatic relief to targeted immune modulation. For clinicians and researchers, this means a greater emphasis on identifying and disrupting eosinophil-driven inflammatory networks. A deeper understanding of eosinophil-driven pathways can improve diagnostic accuracy, enable better patient stratification, and lead to more effective, personalized treatments for EoE. The promising efficacy of emerging biologic therapies targeting type 2 inflammation suggests a future where specific immune pathways are precisely controlled, potentially offering long-term remission and preventing fibrostenotic complications, moving beyond broad immunosuppression.
eosinophilic-esophagitis
eoe
eosinophils
type-2-inflammation
il-4
il-5